25 results on '"Strnad, Joann"'
Search Results
2. Supplementary Table S1 from A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma
3. Supplementary Figure S1 from A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma
4. Structure–activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4′ and C6 variations
5. Novel advances in biotransformation and bioactivation research – 2020 year in review
6. I[kappa]B kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges
7. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
8. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma
9. [10] Somatostatin receptor coupling to G proteins
10. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
11. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
12. Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)
13. Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors
14. Selective Inhibition of Tyrosine Kinase 2 (TYK2) with BMS-986165 Is Efficacious in IL-23-Mediated Diseases: Evidence from Preclinical IBD Models and From a Psoriasis Study
15. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
16. 349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease
17. Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases
18. Tyk2 catalytic activity is required for p40 and interferon-alpha dependent responses (IRM9P.724)
19. Periodic, Partial Inhibition of IκB Kinase β-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis
20. NEMO binding domain of IKK‐2 encompasses amino acids 735–745
21. BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice
22. The catalytic subunits of IκB kinase, IKK-1 and IKK-2, contain non-equivalent active sites when expressed as homodimers
23. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
24. Identification of Imidazo[1,2- b ]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
25. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.